IN2015DN04089A - - Google Patents

Info

Publication number
IN2015DN04089A
IN2015DN04089A IN4089DEN2015A IN2015DN04089A IN 2015DN04089 A IN2015DN04089 A IN 2015DN04089A IN 4089DEN2015 A IN4089DEN2015 A IN 4089DEN2015A IN 2015DN04089 A IN2015DN04089 A IN 2015DN04089A
Authority
IN
India
Prior art keywords
enantiomers
signifies
alkyl alkylaryl
alkylheteroaryl
proviso
Prior art date
Application number
Inventor
Da Silva Patrício Manuel Vieira Araújo Soares
Maria João Macedo Da Silva Bonifácio
Original Assignee
BIAL PORTELA & Cª S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BIAL PORTELA & Cª S A filed Critical BIAL PORTELA & Cª S A
Publication of IN2015DN04089A publication Critical patent/IN2015DN04089A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to compounds of formula I: for use in treating pulmonary arterial hypertension and associated conditions where R1 R2 and R3 are the same or different and signify hydrogens halogens alkyl alkylaryl alkyloxy hydroxy nitro amino alkylcarbonylamino alkylamino or dialkylamino group; R4 signifies hydrogen alkyl alkylaryl or alkylheteroaryl; X signifies CH2 oxygen atom or sulphur atom; n is 1 2 or 3 with the proviso that when n is 1 X is not CH2; and the individual (R) and (S) enantiomers or mixtures of enantiomers and pharmaceutically acceptable salts thereof.
IN4089DEN2015 2012-11-14 2013-11-14 IN2015DN04089A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261726119P 2012-11-14 2012-11-14
PCT/PT2013/000065 WO2014077715A1 (en) 2012-11-14 2013-11-14 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury

Publications (1)

Publication Number Publication Date
IN2015DN04089A true IN2015DN04089A (en) 2015-10-09

Family

ID=49759506

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4089DEN2015 IN2015DN04089A (en) 2012-11-14 2013-11-14

Country Status (23)

Country Link
US (3) US9604970B2 (en)
EP (1) EP2919780B1 (en)
JP (1) JP6373275B2 (en)
KR (1) KR102259938B1 (en)
CN (1) CN105025895B (en)
AU (1) AU2013345494B2 (en)
BR (1) BR112015010969B1 (en)
CA (1) CA2890920C (en)
CY (1) CY1120953T1 (en)
DK (1) DK2919780T3 (en)
ES (1) ES2693025T3 (en)
HK (1) HK1215393A1 (en)
HR (1) HRP20181651T1 (en)
IN (1) IN2015DN04089A (en)
LT (1) LT2919780T (en)
MX (1) MX355422B (en)
PL (1) PL2919780T3 (en)
PT (1) PT2919780T (en)
RS (1) RS57874B1 (en)
RU (1) RU2718055C2 (en)
SI (1) SI2919780T1 (en)
TR (1) TR201815850T4 (en)
WO (1) WO2014077715A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102259938B1 (en) 2012-11-14 2021-06-03 바이알 - 포르텔라 앤드 씨에이 에스에이 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623107B2 (en) * 1990-11-16 1994-03-30 帝人株式会社 Pharmaceutical composition containing prostacyclin as an active ingredient
RU2145321C1 (en) * 1994-04-26 2000-02-10 Синтекс (Ю.Эс.Эй) Инк. Benzocycloalkylazolothione derivatives
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
CA2412856A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
GB0600709D0 (en) * 2006-01-13 2006-02-22 Portela & Ca Sa Drug combinations
GB0610804D0 (en) * 2006-05-31 2006-07-12 Portela & Ca Sa New crystal forms
GB0700635D0 (en) * 2007-01-12 2007-02-21 Portela & Ca Sa Therapy
WO2008137148A2 (en) * 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
JP2011506315A (en) * 2007-12-05 2011-03-03 バイアル−ポルテラ アンド シーエー，エス．エー． New salts and crystal forms
BRPI0821970A2 (en) * 2008-01-03 2015-06-23 Biomarin Pharm Inc Pterine analogs for bh4 responsive condition treatment
AR070841A1 (en) * 2008-03-13 2010-05-05 Bial Portela & Ca Sa ASYMMETRIC CATALYTIC HYDROGENATION PROCESS
AR071632A1 (en) * 2008-05-06 2010-06-30 Bial Portela & Ca Sa CATALYTIC PROCESS FOR ASYMMETRIC HYDROGENATION IN THE SYNTHESIS OF INHIBITORS OF DOPAMINE-BETA-HYDROXYLASE "
DE102008054205A1 (en) * 2008-10-31 2010-05-06 Bayer Schering Pharma Aktiengesellschaft Use of helium-oxygen gas mixtures for the treatment of pulmonary arterial hypertension
RU2604734C2 (en) * 2010-12-22 2016-12-10 БИАЛ-ПОРТЕЛА энд КА., С.А. Crystalline form and method of cleaning same
KR102259938B1 (en) 2012-11-14 2021-06-03 바이알 - 포르텔라 앤드 씨에이 에스에이 1,3-dihydroimidazole-2-thione derivatives for use in the treatment of pulmonary arterial hypertension and lung injury

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021005623A1 (en) * 2019-07-08 2021-01-14 Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. A vaccine formulation for protection against enterotoxigenic e. coli (etec) and cholera

Also Published As

Publication number Publication date
US20190241545A1 (en) 2019-08-08
US20150299172A1 (en) 2015-10-22
CY1120953T1 (en) 2020-05-29
HK1215393A1 (en) 2016-08-26
JP6373275B2 (en) 2018-08-15
ES2693025T3 (en) 2018-12-07
BR112015010969A2 (en) 2017-08-22
RU2015120164A (en) 2017-01-10
US9604970B2 (en) 2017-03-28
BR112015010969B1 (en) 2020-05-26
EP2919780B1 (en) 2018-08-01
US20170369477A1 (en) 2017-12-28
CA2890920A1 (en) 2014-05-22
US10308640B2 (en) 2019-06-04
TR201815850T4 (en) 2018-11-21
AU2013345494A1 (en) 2015-05-14
CA2890920C (en) 2020-12-15
CN105025895B (en) 2019-02-26
MX2015005910A (en) 2015-08-10
SI2919780T1 (en) 2018-12-31
KR20150084022A (en) 2015-07-21
RU2718055C2 (en) 2020-03-30
MX355422B (en) 2018-04-18
PT2919780T (en) 2018-11-13
WO2014077715A1 (en) 2014-05-22
JP2016504286A (en) 2016-02-12
KR102259938B1 (en) 2021-06-03
LT2919780T (en) 2018-11-12
AU2013345494B2 (en) 2018-03-22
RS57874B1 (en) 2018-12-31
HRP20181651T1 (en) 2018-12-14
DK2919780T3 (en) 2018-11-26
EP2919780A1 (en) 2015-09-23
CN105025895A (en) 2015-11-04
PL2919780T3 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
MX2017010062A (en) [9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido -[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto.
TW200612958A (en) Substituted imidazole derivatives
GEP201606532B (en) Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
ES2531324T3 (en) Intermediate to produce a bicyclic gamma-amino acid derivative
MX2007004699A (en) Indole and benzimidazole derivatives.
ATE404536T1 (en) SUBSTITUTED QUINOLINE DERIVATIVES AS INHIBITORS OF MITOTIC KINESIN
UA108510C2 (en) Cyclopropane compound
NZ596615A (en) Substituted isoquinoline derivative
TW200716084A (en) Methods for treating sleep-wake disorders
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
GB0708818D0 (en) Compounds
MA35893B1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
MY178106A (en) 1,4-butanediol-containing composition
UA96947C2 (en) Cinnamoyl-piperazine derivatives and their use as par-1 antagonists
AR035521A1 (en) DERIVATIVES OF 3-INDOLIN AND PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM
MX2012007896A (en) Arylsulfonamide pyridine-pyridinone derivatives, preparation of same, and therapeutic use thereof.
MX2011008360A (en) Heteroaryl substituted pyridazinone derivatives.
PH12015502429A1 (en) Dicarboxylic acid compound
BR112015011974A2 (en) azaquinazoline carboxamide derivatives
MY195881A (en) Griseofulvin Compound
CY1120953T1 (en) 1,3-Dihydroimidazole-2-thione derivatives FOR USE IN THE TREATMENT OF PULMONARY ARTERY HYPERTENSION AND PULMONARY DAMAGE
MY160253A (en) Prophylactic or ameliorating agent for pigmentation
PE20141168A1 (en) DERIVATIVES OF PYRAZOLIDIN-3-ONA
MX2015007424A (en) Compositions and/or articles with improved solubility of a solid active.